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Abstract RNase MRP is a conserved endoribonuclease,
in humans consisting of a 267-nucleotide RNA associated
with 7–10 proteins. Mutations in its RNA component lead
to several autosomal recessive skeletal dysplasias, includ-
ing cartilage-hair hypoplasia (CHH). Because the known
substrates of mammalian RNase MRP, pre-ribosomal
RNA, and RNA involved in mitochondrial DNA
replication are not likely involved in CHH, we analyzed the
effects of RNase MRP (and the structurally related RNase
P) depletion on mRNAs using DNA microarrays. We con-
firmed the upregulation of the interferon-inducible viperin
mRNA by RNAi experiments and this appeared to be
independent of the interferon response. We detected two
cleavage sites for RNase MRP/RNase P in the coding
sequence of viperin mRNA. This is the first study provid-
ing direct evidence for the cleavage of a mRNA by
RNase MRP/RNase P in human cells. Implications for
the involvement in the pathophysiology of CHH are
discussed.
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Abbreviations
TERT Telomerase-associated
reverse transcriptase
CHH Cartilage-hair hypoplasia
ITS1 Internal transcribed spacer 1
RMRP RNase MRP RNA
AD Anauxetic dysplasia
IFN-a Interferon-a
TAM-bodies Temporal asymmetric
MRP bodies (TAM-bodies)
Introduction
The RNase MRP complex is a ubiquitously expressed
essential eukaryotic ribonucleoprotein particle consisting
of an RNA component and at least seven proteins (hPop1,
hPop5, Rpp20, Rpp25, Rpp30, Rpp38, and Rpp40) [1–3].
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Three additional proteins are associated with at least a
subset of RNase MRP particles: Rpp14, Rpp21 and Rpp29
(hPop4) [2]. RNase MRP is localized primarily in the
nucleolus and functions as an endoribonuclease. It is
responsible for the generation of the RNA primer that is
needed for mitochondrial DNA replication [4], mediates
cleavage of the internal transcribed spacer 1 sequence in
pre-rRNA, a step in the maturation of rRNA [5], and, in
yeast, is required for entry of the precursor rRNA into the
canonical processing pathway [6]. In addition, RNase
MRP has been implicated in the cell cycle as a result
of its capacity to cleave the 50UTR of the cyclin-B2
mRNA [7]. Interestingly, it was recently reported that the
RNA component of human RNase MRP, RMRP, forms a
complex with the telomerase-associated reverse trans-
criptase (TERT) [8]. The TERT–RMRP complex exhibits
RNA-dependent RNA polymerase activity and produces
dsRNAs that are processed into siRNAs by Dicer. One of
these siRNAs is directed against the RMRP itself. This
way the level of RNase MRP RNA is controlled by the
association with TERT via a negative-feedback mecha-
nism [8].
So far, there is no substrate recognition sequence iden-
tified for RNase MRP. Secondary and tertiary structural
elements are believed to play an important role in the
substrate selection by RNase MRP.
Human RNase MRP shares all of its known protein
components with RNase P, an evolutionary related endo-
ribonuclease that cleaves the 50 leader of pre-tRNA, and
thus is involved in tRNA maturation [9]. In addition,
human RNase P has been demonstrated to play a role in
transcription by polymerase I and III [10, 11]. Bacterial
RNase P consists of a RNA component (M1 RNA) and the
protein C5. Throughout evolution from prokaryotes to
eukaryotes, RNase P acquired an increasing amount of
protein subunits [12]. The human RNase P complex con-
tains at least ten associated proteins.
The human genetic disorder CHH (OMIM250250) [13]
is caused by mutations in the RMRP gene [14]. CHH is
inherited in an autosomal recessive manner and patients are
characterized by a short stature, hypoplastic hair, and short
limbs. In addition, they show a predisposition to lympho-
mas and other cancer types (primarily hematopoietic),
Hirschsprung’s disease, bronchiectasis, childhood anemia
and suffer from a defective T-cell immunity [15–20].
CHH-associated mutations are either located in the tran-
scribed sequence or in the promoter region of the RMRP
gene. So far, more than 70 different CHH-associated
mutations have been identified in the 267-nt-long coding
region. Between the TATA box and the transcription ini-
tiation site, 25 different insertions, duplications, and
triplications have been reported [21]. Promoter mutations
lead to a diminished or abrogated synthesis of RNase MRP
RNA [14]. CHH patients either have a combination of two
RNase MRP RNA mutations in both alleles or a combi-
nation of a RNase MRP RNA mutation in one allele and a
promoter mutation in the other allele, although recently a
patient has been reported that carries a combination of two
promoter mutations [22]. RMRP mutations lead to a very
large heterogeneity in clinical phenotypes, even between
family members with the same mutations [23, 24]. In
addition to CHH, RMRP mutations have also been found in
anauxetic dysplasia (AD, MIM #607095). AD patients
suffer from mild mental retardation and hypodontia and
display a shorter stature than CHH patients [21, 25].
The aim of this study was to identify mRNA targets of
human RNase MRP. RNase MRP levels were reduced by
siRNA-mediated knock-down of its protein subunits and a
global mRNA analysis revealed the upregulation of a.o. the
viperin mRNA. The upregulation of viperin was confirmed
at both the mRNA and protein level. The results are con-
sistent with the direct cleavage of the viperin mRNA by
RNase MRP.
Materials and methods
Cell culture and reagents
HEp-2 and HeLa were maintained in DMEM ? Glutamax
supplemented with 10% heat-inactivated fetal calf serum
(FCS) in a humidified 37C, 5% CO2 incubator. We pur-
chased Interferon-aA/D and poly(I:C) from Sigma.
Antibodies
Monoclonal antibodies used: Rpp20-specific antibody
(IFII, Modiquest), GST-specific antibody (2A9, Modi-
quest), c-tubulin-specific antibody (GTU-88, Abcam) and
viperin-specific antibody (MaP.VIP) [26]. Polyclonal rab-
bit sera against hPop1, Rpp25, and Rpp40 were a kind gift
of Sidney Altman. Polyclonal rabbit sera against hPop4 and
U3-55K were described previously [27, 28].
Immunoblotting
For immunoblot analysis, proteins were separated by
SDS-PAGE and transferred to nitrocellulose membranes by
electroblotting. As secondary antibodies, we used the
IRDye 800CW Goat Anti-Mouse Secondary Antibody
(LiCOR Biosciences) and IRDye 800CW Goat Anti-Rabbit
Secondary Antibody (LiCOR Biosciences). We used the
Odyssey imaging system (LiCOR Biosciences) for imaging
and quantifying of signals.
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RNA interference
The siRNAs against Rpp20, Rpp25 and hMtr4 were
published previously [29, 30]. We purchased the siRNAs
against hPop1 (50-GAAUUUAACCGUAGACAAAd
TdT-30), Rpp40 (50-CCUUAAACUUGGAUUCUAAdT
dT-30) and EGFP (50-CGAGAAGCGCGAUCACAUGdT
dT-30) from Eurogentec.
For a typical siRNA experiment in 6-well plates,
1.25 9 105 cells were transfected with 20 pmol of siRNA
using Oligofectamine reagent (Invitrogen) according to the
manufacturer’s instructions with the exception that the
medium contains 10% FCS during transfection. Cells were
harvested 48 h after siRNA transfection.
Transfection
The pcDNA3.1 constructs containing the coding region of
human viperin or the coding region flanked by the 50 and
30-UTRs were generated by PCR amplification using gene-
specific primers (GenBank Accession Number NM_08
0657) containing EcoRI and BamHI restriction sites and
cDNA from human foreskin fibroblasts as a template. The
purified PCR products were digested with EcoRI and
BamHI and cloned into the EcoRI and BamHI restriction
sites of pcDNA3.1.
We transfected HeLa cells with the viperin constructs
and the pEBG plasmid encoding GST [31] (transfection
control) using FuGENE 6 (Roche) according to the manu-
facturer’s instructions. Twenty-four hours after transfection
with plasmids, the cells were treated with the siRNAs as
described above.
In vitro activity assays
PCR was performed to generate the RNA substrates for
in vitro transcription by T7 RNA polymerase, using the
following primers. For viperin 151–250: 50-GGGTAAT
ACGACTCACTATAGGGCTGGTCCTGAGAGGGCC-30
and 50-TGCACTGGCGAGTGAAGTGATAGTTGACGC-
30; for viperin 401–500: 50-GGGTAATACGACTCA
CTATAGGGAATACCTGGGCAAGTTG-30 and 50-TGG
AACCACCTCTCCCG-30; for viperin 451–550: 50-GGGT
AATACGACTCACTATAGGGAGCGTGAGCATCGTG
AGC-30 and 50-CAAAGCTGTCACAGGAG-30; for vip-
erin 751–850: 50-GGGTAATACGACTCACTATAGGGC
TCTTAATTGAGGGTG-30 and 50-TGTGGCGCTCCAAG
AATCTTTCAAATTC-30 and for viperin 851–950: 50-G
GGTAATACGACTCACTATAGGGAAGAAGTGTCCT
GCTTG-30 and 50-CGTCCCTTTCTACAGTTC-30. The
resulting templates were in vitro transcribed by T7 RNA
polymerase using 32P-labeled UTP. For the pre-tRNA
substrate the yeast suppressor precursor tRNASer (pSupS1)
plasmid [32] was linearized with TaqI and in vitro
transcribed by SP6 RNA polymerase in the presence of
32P-labeled UTP.
Antibodies were coupled to Protein-A agarose beads,
which were used for immunoprecipitation of RNase
MRP/P from HEp-2 cell extracts as described elsewhere
[2]. 12.5 ll of 29 cleavage buffer (40 mM HEPES–KOH,
pH 7.6, 20 mM MgCl2, 100 mM KCl, 2 mM DTT, and
100 lg/ml BSA) was added to the immunoprecipitates still
attached to the beads. Then 12.5-ll radiolabeled RNA
substrate solution containing 0.3 U/ll RNasin (Promega)
was added to the beads and the reaction mixtures were
incubated at 37C (10 min for pre-tRNA, 60 min for
viperin mRNA). The reaction was terminated by adding
Trizol (Invitrogen). Subsequently, the RNA was isolated
and analyzed on an 8% (v/v) denaturing polyacrylamide
gel. A phosphorimager was used to visualize the radiola-
beled RNA in the gel.
Inactivation by micrococcal nuclease
Antibodies against hPop4 or pre-immune serum were
coupled to Protein A-agarose beads for the immunopre-
cipitation of RNase MRP/P from HEp-2 cell extracts as
described elsewhere [2]. The precipitates were pre-incu-
bated in a 4-ll volume containing 1 mM CaCl2, or 1 mM
CaCl2 plus micrococcal nuclease (0.5 U/ll), or micrococ-
cal nuclease (0.5 U/ll) plus 20 mM EGTA for 15 min at
37C. Subsequently, 1 ll of 0.1 M EGTA was added. As a
control, half of the reactions that had been incubated with
CaCl2 and micrococcal nuclease did not receive EGTA to
monitor the effect of active micococcal nuclease on the
viperin substrates. After the addition of 12.5 ll of 29
cleavage buffer and 7.5 ll of radiolabeled substrate RNA
solution containing 0.3 U/ll RNasin (Promega), the reac-
tion mixtures were incubated for 1 h at 37C. RNA was
then isolated and analyzed as described above.
Northern-blot hybridization
We performed Northern blotting and hybridization as
described previously [2]. Hybridization with internally
32P-labeled antisense riboprobes against the RNA compo-
nents of RNase MRP and RNase P was performed at 65C,
for 32P-end-labeled antisense oligonucleotides comple-
mentary to U1 snRNA (50-GCGCGAACGCAGTCCCCCA
CTACCAC-30) at 42C.
Microarray analysis
We performed four independent transfections of HEp-2
cells with siRNAs against EGFP, hPop1, and Rpp40. Cells
were harvested 48 h after transfection. Knock-down of
RNase MRP/P cleaves viperin mRNA 2471
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hPop1 and Rpp40 was monitored by Western blotting.
RNA was isolated using Trizol (Invitrogen) and purified
using the RNeasy kit (Qiagen). The resulting RNAs were
subjected to microarray analysis in the laboratory of Prof.
Frank Holstege (Utrecht University, The Netherlands)
using human 70-mer oligos (Operon, Human V2 AROS)
spotted onto Codelink Activated slides (Surmodics) 21K
arrays. Two sets of two biological replicates were analyzed
with reverse fluorochromes. The expression profiles
obtained with material of sihPop1- and siRpp40-treated
cells were compared to that obtained for the control
siEGFP-treated material. RNA amplifications, labeling,
and hybridizations were performed as described [33].
cRNA (2,500 ng) coupled to Cy3 and Cy5 fluorophores
(Amersham) were hybridized on a Tecan HS4800PRO and
scanned on an Agilent scanner (G2565BA) at 100% laser
power, 30% PMT. After data extraction using Imagene 8.0
(BioDiscovery), printtip Loess normalization was per-
formed [34] on mean spot-intensities without background
subtraction. Data was analyzed using ANOVA (R version
2.2.1/MAANOVA version 0.98-7) (http://www.r-project.
org/) [35]. In a fixed-effect analysis, sample, array, and dye
effects were modeled. p values were determined by a per-
mutation **F2-test, in which residuals were shuffled 5,000
times globally. Genes with p \ 0.05 after family-wise error
correction were considered significantly changed. Micro-
array data have been deposited with ArrayExpress under
Accession no. E-TABM-981.
Results
siRNA-mediated RNase MRP and RNase P depletion
To investigate whether the levels of RNase MRP in HEp-2
cells can be reduced by an siRNA-mediated knock-down
approach, we transfected the cells with siRNAs against the
hPop1, Rpp20, Rpp25, and Rpp40 mRNAs. Forty-eight
hours after transfection the cells were lysed and the pro-
teins were analyzed by Western blotting. The levels of each
of the targeted proteins appeared to be reduced by the
respective siRNA treatments, although the efficiency of
knock-down varied and the siRpp25 appeared to be the
least effective (Fig. 1a). Since the reduced levels of these
proteins may affect the stability of the complex, we mon-
itored the level of the RNA component of RNase MRP by
Northern-blot hybridization, using U1 snRNA as a control.
The reduction of hPop1, Rpp20, Rpp40 and, to a lesser
extent, Rpp25, led to a concomitant decrease of RNase
MRP RNA levels (Fig. 1b). These results indicate that a
depletion of one of the protein components leads to
destabilization and, as a result, reduced levels of the whole
complex. Because the depleted proteins are also associated
with the RNase P complex, the effects on RNase P RNA
levels were investigated as well. As expected, very similar
effects were observed for the levels of RNase P RNA
(Fig. 1b).
Gene expression profiles after hPop1
or Rpp40 knock-down
To identify mRNA substrates for the human RNase MRP
complex, we examined the effects of siRNA-mediated
depletion of RNase MRP (and RNase P) on the transcrip-
tome of HEp-2 cells. We knocked-down the expression of
two RNase MRP protein components, hPop1 and Rpp40,
and after 48 h isolated mRNA from these cells as well as
from cells transfected with an siRNA targeting the GFP
mRNA (siEGFP), which was used as a control. The
expression levels of mRNAs were analyzed on a genome-
wide scale using 21K microarrays. When compared to the
control, 95 genes displayed at least twofold differences
after knocking-down either hPop1 or Rpp40 (Supplemen-
tary Table 1 and Supplementary Table 2 online). Seven of
these were more than twofold upregulated in both datasets
(RSAD2, CASP7, CAPNS1, SYPL1, H3F3A, DDT, and
ARPC1A) and four genes were more than twofold down-
regulated (HMOX1, NQO1, IL8, and GCLM) (Table 1). In
accordance with previously reported CHH patient micro-
arrays data, the differentially expressed genes are primarily
associated with the immune system and apoptosis [37].
Fig. 1 siRNA-mediated knock-down of RNase MRP and P protein
components leads to complex instability. a Immunoblotting using
antibodies against hPop1, Rpp20, Rpp25, Rpp40, and c-tubulin
(loading control). b Northern-blot hybridization analysis of total
RNA. U1 snRNA was used as a loading control and MRP and P RNA
levels after siRNA treatment are depicted relative to those observed
after siEGFP treatment. Results are presented as the mean of three
independent experiments ± SEM
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Viperin upregulation upon RNase MRP/RNase P
knock-down
Direct mRNA targets for RNase MRP are predicted to be
upregulated upon a reduction of RNase MRP function.
Only a single mRNA was found to be upregulated more
than twofold in both datasets (hPop1 and Rpp40 knock-
down) as well as in four CHH patients, from which
leukocyte mRNA was analyzed in two independent
microarray studies ([37] and P. Hermanns, unpublished
results). This prompted us to investigate the effects of
RNase MRP on this transcript in more detail. This mRNA
is transcribed from the RSAD2 gene and is translated into
the anti-viral protein viperin [38]. First, we analyzed
whether RNase MRP depletion affected the expression of
this gene at the protein level by Western blotting. In
agreement with the microarray data, the viperin protein
was indeed upregulated in HEp-2 cells, not only upon
siRNA-mediated knock-down of hPop1 and Rpp40, but
also after knock-down of two other RNase MRP protein
components, Rpp20 and Rpp25 (Fig. 2). The effects
observed for depletion of the latter protein were modest,
which is in agreement with the generally poor reduction
in Rpp25 and RNase MRP RNA levels (Fig. 1). These
results demonstrate that the expression of viperin also at
the protein level is modulated by RNase MRP and/or
RNase P.
Viperin upregulation is not affected by interferon
The expression of viperin is known to be induced by type I
interferons [38]. Indeed, interferon-a (IFN-a) treatment of
HEp-2 cells resulted in elevated viperin expression levels,
which appeared to be even higher when the cells were also
exposed to poly (I:C), a well-documented inducer of
interferon (Fig. 3). To investigate whether viperin upregu-
lation by RNase MRP depletion was independent of
upregulation by the interferon response, we stimulated
siRNA-treated HEp-2 cells with IFN-a for 16 h prior to
harvesting. Also after interferon induction the levels of both
viperin protein and mRNA, as determined by quantitative
RT-PCR, were elevated upon RNase MRP knock-down
(Fig. 3a and data not shown). Moreover, the cumulative
induction of viperin expression was also evident when the
cells were exposed to both IFN-a and poly(I:C) (Fig. 3b).
These results are consistent with the elevation of viperin
expression at the transcriptional level by interferon and at
the post-transcriptional level by RNase MRP.
Viperin upregulation is not due to rRNA
processing defects
To exclude that viperin upregulation after RNase MRP
knock-down is due to rRNA processing defects (arising
from the RNase MRP knockdown), we transfected HEp-2
Table 1 Differentially expressed genes after siRNA-mediated knock-down of hPop1 or Rpp40 in HEp-2 cells compared to control transfected
cells
Gene
symbol
Description hPop1a Rpp40a GO-term biological processb
RSAD2 Viperin 3.6 2.0 Defense response to virus
SYPL1 Synaptophysin-like
protein 1
3.2 2.5 Transport/synaptic transmission
ARPC1A Actin-related protein 2/3
complex subunit 1A
2.5 2.9 Actin cytoskeleton organization
CASP7 Caspase-7 precursor 2.5 2.1 Release of cytochrome c from mitochondria/apoptosis
H3F3A Histone H3.3 2.5 2.9 Nucleosome assembly
DDT D-dopachrome
decarboxylase
2.4 2.4 Melanin biosynthetic process from tyrosine
CAPNS1 Calpain small subunit 1 2.3 2.0 Positive regulation of cell proliferation
NQO1 NAD(P)H dehydrogenase
[quinone] 1
-4.6 -3.0 Xenobiotic metabolic process/nitric oxide biosynth. Process/response to oxidative
stress/synaptic cholinergic/toxin resp./neg. regulation of catalytic
activity/oxidation reduction
HMOX1 Heme oxygenase 1 -3.5 -3.5 Heme oxidation
IL8 Interleukin-8 precursor -2.3 -3.4 Angiogenesis/immune response/cell motion/inflammatory response/cell–cell
signaling/negative regulation of cell proliferation/cell adhesion
GCLM Glutamate–cysteine ligase
regulatory subunit
-2.0 -2.1 Cysteine metabolic proc./glutathione metabolic process/neg. regulation
of apoptosis/regulation of blood vessel size
a Only genes more than twofold up- or down-regulated by both the hPop1 and Rpp40 knock-downs are shown
b GO-terms listed are from the Gene Ontology Consortium [36]
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cells with an siRNA against Mtr4, in parallel with siRNAs
for EGFP, hPop1 and Rpp20. Mtr4 is an exosome-associ-
ated protein, and depletion of this protein causes the
accumulation of 5.8S rRNA precursors [30]. Sixteen hours
prior to harvesting of the cells, IFN-a (1,000 U/ml) was
added to the medium. No viperin upregulation was
observed after knock-down of Mtr4 (Fig. 4). In addition, in
a separate study, in which we targeted hXrn1 (a 50–30
exoribonuclease), hDis3 (a 30–50 exoribonuclease), hRrp41
or hPM/Scl-100 (exosome components) by siRNA in
HEp-2 cells and analyzed the effects on mRNA expression
by microarrays, no upregulation of viperin mRNA was
observed (unpublished data). These results strongly suggest
that the observed changes in viperin expression are not due
to indirect effects of interfering with RNase MRP/P
function.
Viperin upregulation does not require
non-coding sequences
Viperin expression cannot be induced in HeLa cells, not
even after stimulation with IFN-a (Fig. 5a; [38]). This
implies that the HeLa cell line is very suitable for trans-
fection experiments, in which viperin is ectopically
expressed, since the endogenous protein will not affect the
interpretation of the results. To study the importance of
coding sequence and UTRs for the regulation of viperin
expression by RNase MRP/P, we transfected HeLa cells
with constructs containing the viperin coding sequence
either with or without the 50 and 30 UTRs. Subsequently,
we subjected the cells to siRNA-mediated knock-down of
RNase MRP/P components. Western-blot analysis of cell
lysates showed that with both constructs viperin was
upregulated in the siRNA treated cells (Fig. 5b). These
results indicate that the induction of viperin by RNase
Fig. 2 Viperin protein level is upregulated after RNase MRP/P
knock-down. a Western-blot analysis of viperin 48 h post siRNA
treatment of HEp-2 cells. c-tubulin was used as a loading control.
b Viperin protein signals on the Western blots were quantified and are
depicted relative to the levels observed upon treatment with the
siEGFP. Results are presented as the mean of three independent
experiments ± SEM
Fig. 3 Viperin upregulation by RNase MRP/P knock-down also
occurs in IFN-a and poly(I:C) stimulated cells. a siRNA-treated
HEp-2 cells were stimulated with 1,000 U/ml IFN-a 16 h prior to
harvesting the cells. Forty-eight hours after siRNA transfection, the
cells were lysed and viperin expression was analyzed by immuno-
blotting, using c-tubulin as a loading control. b siRNA-treated HEp-2
cells were stimulated with 5,000 U/ml IFN-a and where indicated
also with 100 lg/ml poly(I:C) 16 h prior to harvesting the cells.
Forty-eight hours after siRNA transfection, the cells were lysed and
viperin expression was analyzed by immunoblotting, using c-tubulin
as a loading control
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MRP/P knock-down is not dependent on UTR sequences
and also confirm that this phenomenon does not require the
promoter of the viperin gene. As a consequence, the coding
sequence of viperin mRNA most likely contains the puta-
tive cleavage site(s) for RNase MRP/P.
RNase MRP or RNase P cleaves viperin mRNA in vitro
The results of transfection experiments with constructs
encoding distinct parts of the 1,086-nt-long coding
sequence of viperin mRNA suggested that the region tar-
geted by RNase MRP/P is located in the central part of the
coding sequence (data not shown). To investigate whether
RNase MRP or RNase P are indeed capable to cleave the
viperin mRNA in this region, we incubated radiolabeled
segments of the coding sequence of the viperin mRNA
with RNase MRP/P in vitro. We immunoprecipitated
RNase MRP and RNase P from HEp-2 cell extracts by
antibodies against hPop4 and Rpp25 antibodies. As con-
trols, we used normal rabbit serum and an antibody against
the 55K protein component of the U3 snoRNP in parallel.
Several 100 nucleotides long viperin mRNA segments and
pre-tRNA as a control were transcribed in vitro and added
to the immunoprecipitates. The immunoprecipitated RNase
MRP/P efficiently converted the pre-tRNA substrate in the
expected products of 28 and 82 nucleotides, corresponding
to the 50 leader and tRNA body, respectively (Fig. 6). In
three of the 100-nt viperin mRNA substrates cleavages
were observed after incubation with the precipitates of the
antibodies against hPop4 and Rpp25. Importantly, the
corresponding cleavage products did not appear after
incubation with the precipitates obtained with the normal
rabbit and 55K-specific antibodies. Since two of the three
cleaved substrates contained overlapping sequences, these
results are consistent with the presence of two RNase
MRP/P cleavage sites, one located between nucleotides
451 and 500 of the coding sequence of viperin mRNA and
the other located between nucleotides 851 and 950. Addi-
tional controls with similarly sized segments of the
mRNAs encoding peptidylarginine deiminase 2 and tissue
transglutaminase 2, two unrelated mRNAs, the expression
levels of which were not altered upon RNase MRP/P
depletion (microarray data), confirmed the specificity of
viperin mRNA cleavage, because no cleavage of these
RNAs could be detected (results not shown).
To obtain additional evidence that the cleavage of viperin
mRNA is due to the activity of RNase MRP/P, which will be
dependent on its RNA component, the immunoprecipitated
RNase MRP/P was pre-incubated with micrococcal nuclease
(Fig. 7). Micrococcal nuclease treatment followed by inac-
tivation of this enzyme by the addition of EGTA prior to the
in vitro cleavage reaction abrogated the cleavage of viperin
mRNA segments by RNase MRP/P. This effect was not due
to the presence of calcium during the pre-incubation with
micrococcal nuclease, nor to other activities present in the
micrococcal nuclease preparation, as demonstrated by the
controls. As expected, when micrococcal nuclease was not
inactivated by the addition of EGTA, this enzyme led to
additional cleavages in the viperin mRNA segments. Taken
together, these results indicate that an intact RNA compo-
nent in the RNase MRP/P preparation is essential for the
cleavage activity.
Discussion
The results of this study identify the viperin mRNA as a
new substrate for the human RNase MRP and/or RNase P
Fig. 4 Viperin upregulation is not due to rRNA processing defects.
HEp-2 cells treated with the indicated siRNAs were stimulated with
1,000 U/ml IFN-a for 16 h prior to harvesting the cells. Forty-eight
hours after siRNA transfection, cell lysates were analyzed by
immunoblotting, using c-tubulin as a loading control
Fig. 5 The coding region of the viperin mRNA is sufficient for its
elevated translation in cells depleted of RNase MRP/P. a Viperin
expression in HEp-2 and HeLa cells that were subjected to increasing
concentrations of IFN-a for 16 h before harvesting was analyzed by
immunoblotting. The concentration of IFN-a ranged from 0 to
1,000 U/ml. As a control, c-tubulin was analyzed in parallel. b HeLa
cells were transfected with a pcDNA3.1 construct containing the
coding sequence of viperin with or without the 50 and 30 UTRs. The
cells were co-transfected with a GST-coding plasmid, which served as
a transfection control. After 24 h, the cells were treated with the
indicated siRNAs. Forty-eight hours after siRNA transfection, cell
lysates were analyzed by immunoblotting using antibodies specific for
viperin and GST
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complex. We have shown that viperin expression is
induced both at the protein and at the mRNA level in
human cell lines after knock-down of RNase MRP- and
RNase P-associated proteins. Viperin upregulation by
RNase MRP/P depletion appeared to be independent of
IFN-a and poly(I:C), two well-known inducers of inter-
feron responsive genes, a.o. viperin. In agreement with the
ribonuclease activity of RNase MRP/P, the observed
induction of viperin expression is not dependent on non-
transcribed elements of the viperin gene. In addition, this
phenomenon does not seem to be due to specific sequence
elements in the UTRs of the viperin mRNA. Taken toge-
ther, our data indicate that viperin expression is repressed
by RNase MRP or RNase P as a result of endoribonucle-
olytic cleavages in the coding sequence of the viperin
mRNA.
Although the number is relatively low, our microarray
data identified several other putative mRNA substrates for
the human RNase MRP/P. Interestingly, the cyclin-B2
mRNA, which was reported by Thiel and coworkers to be
modulated by the human RNase MRP [24], was not
upregulated upon hPop1 or Rpp40 knock-down. This dis-
crepancy will be further discussed below. Among the genes
upregulated upon RNase MRP/P depletion a number of
interferon-regulated genes can be discerned. Currently, it is
unclear whether this is a common feature related to the
activities of RNase MRP/P, or whether this is caused by the
siRNA treatment. Interestingly, an enrichment of inter-
feron-regulated genes was also observed in the dataset
obtained with material from CHH-patient cells [37]. Future
studies will clarify whether the other putative mRNA
substrates are indeed modulated by RNase MRP/P and
whether they are directly cleaved by this enzyme.
The in vitro cleavage experiments provide evidence for
two RNase MRP/P cleavage sites in the coding sequence of
the viperin mRNA. The possibility that in addition to the
cleavages in the mature mRNA, also cleavages in introns
present in the viperin pre-mRNA affect its expression
cannot be excluded.
An important question that is not directly answered by
the results of our experiments is whether the viperin
mRNA is cleaved by RNase MRP or RNase P. Our strategy
to reduce RNase MRP levels by siRNA-mediated knock-
down of its protein components leads to the simultaneous
depletion of RNase P. To distinguish between these two
ribonucleases we tried to reduce their levels by siRNAs
Fig. 6 Cleavage of viperin mRNA fragments by RNase MRP/P in
vitro. HEp-2 cell extracts were subjected to immunoprecipitation by
immobilized antibodies against hPop4, Rpp25, the U3-55K protein,
and antibodies from normal rabbit serum (NRS). The resulting
precipitates were incubated with pre-tRNA, which was used as a
positive control and five different segments of the viperin coding
sequence. Numbers indicate the 50 and 30 nucleotides of these
segments and correspond to their position in the coding sequence. The
reaction products were analyzed by denaturing gel electrophoresis.
The numbers on the left indicate the size of the pre-tRNA, 110 nts, the
cleaved tRNA, 82 nts, the cleaved 50 leader, 28 nts, and the viperin
segments, 100 nts. The input lanes contain the radiolabeled RNAs that
were not incubated with the precipitated material. The most
prominent cleavage products are marked by asterisks
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targeting their RNA components. Although, these are not
mRNAs, the feasibility of this approach was recently
demonstrated by Maida and colleagues [8], who used
RNase MRP RNA-specific siRNAs to knock-down the
levels of RNase MRP. However, none of the four siRNAs
that we used, one of which corresponds to that successfully
applied by Maida and colleagues, showed a significant
effect on RNase MRP RNA or RNase P RNA levels (data
not shown). Currently, it is unclear why the previously
reported RNase MRP RNA-specific siRNA does not work
in our hands. In spite of the lack of direct evidence, we
propose that the post-transcriptional regulation of viperin
expression is mediated by RNase MRP and not by RNase
P. This is most strongly supported by previously published
observations that viperin mRNA levels are upregulated in
cells from CHH patients, in which the function of RNase
MRP is affected as a result of mutations in the RNase MRP
RNA gene, whereas the function of RNase P is unaffected
[37]. In addition, the recently reported association with
TERT can regulate RNase MRP RNA levels by a negative-
feedback mechanism [8]. When TERT is overexpressed,
RNase MRP RNA levels are downregulated. If RNase
MRP, and not RNase P, controls viperin mRNA expres-
sion, this messenger is expected to be induced upon TERT
overexpression. Indeed, when TERT was transduced into
CD4-positive T-cells, viperin mRNA levels were elevated
[39]. Future studies, in which for example the wild-type
RNase MRP RNA gene in mammalian cells is replaced by
a CHH-like mutant gene, will have to provide further
evidence to support the involvement of RNase MRP and
not that of RNase P.
The levels of RNase MRP/P as a result of knocking-
down hPop1 or Rpp40 are similar to what would be
expected in heterozygous carriers of RMRP promoter
mutations, which display no phenotypes. The difference
might be explained by the fact that, in contrast to the cells
of such carriers, siRNA-treated cultured cells will show
much more heterogeneity with regard to the remaining
levels of RNase MRP/P. In addition, rapidly dividing cul-
tured cells may be more critically dependent on RNase
MRP/P levels than cells of such carrier individuals. In this
context it is important to mention that retarded growth was
indeed observed for the cells in which RNase MRP/P was
downregulated. The role of RNase MRP/P in the regulation
of viperin expression is further supported by the observa-
tion that the efficiency of knocking-down RNase MRP/P
components inversely correlates with the efficiency of
viperin upregulation (compare the results in Fig. 1 with
those in Fig. 2).
RNase MRP is localized predominantly in the nucleolus,
which raises the question where the viperin mRNA, and
possibly other mRNAs, are cleaved by RNase MRP. In
Saccharomyces cerevisiae RNase MRP has been reported
to localize to specific cytoplasmic temporal asymmetric
MRP bodies (TAM-bodies) after the initiation of mitosis
[40]. It is possible that RNase MRP degrades specific
mRNAs in these TAM-bodies. In human cells, RNase MRP
components appear to be regulated in a cell-cycle depen-
dent manner, but it is not known whether TAM bodies exist
in mammalian cells as well [11]. The nucleolar association
of human RNase MRP does not appear to be very strong,
because upon actinomycin D treatment (to block tran-
scription) or adenoviral infection hPop1 translocates from
the nucleolus to the nucleoplasm [41, 42]. These data do
not rule out the possibility that low concentrations of
RNase MRP reside in the cytoplasm of human cells and
that this concentration is increased upon cell physiological
changes. Therefore, it is currently impossible to predict in
Fig. 7 The viperin mRNA cleavage activity of RNase MRP/P in
vitro is nuclease-sensitive. HEp-2 cell extracts were subjected to
immunoprecipitation by immobilized antibodies against hPop4 and
antibodies from normal rabbit serum (NRS) as a control. The
immunoprecipitates were subjected to incubation with micrococcal
nuclease, as described in the ‘‘Materials and methods’’ section.
Subsequently, the precipitates were incubated with different segments
of the viperin mRNA. Numbers indicate the 50 and 30 nucleotides of
these segments and correspond to their position in the coding
sequence. The reaction products were analyzed by denaturing gel
electrophoresis. The input lanes contain the radiolabeled RNAs that
were not incubated with the precipitated material. S standard reaction,
no pre-incubation; C pre-incubation with CaCl2, addition of EGTA
prior to the cleavage reaction; MN pre-incubation with micrococcal
nuclease and CaCl2, no addition of EGTA prior to cleavage reaction;
MNE pre-incubation with micrococcal nuclease and CaCl2, addition
of EGTA prior to cleavage reaction; PMN pre-incubation with
micrococcal nuclease, CaCl2, and EGTA. The most prominent
cleavage products are marked by asterisks. The numbers on the left
indicate the positions of a 82-nts tRNA, a 28-nts 50 leader of pre-
tRNA, and the 100-nts viperin mRNA segments
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which subcellular compartment the viperin mRNA is
cleaved by RNase MRP.
Viperin is an anti-viral protein that is induced by type I
and II interferons, LPS or viral infections [38]. It is highly
conserved between mammals and lower vertebrates
[38, 43]. The expression of this protein inhibits influenza A
virus release from the plasma membrane of infected cells,
and also has been demonstrated to interfere with the rep-
lication of hepatitis C virus and human cytomegalovirus
[26, 38]. Viperin localizes to the cytoplasmic side of the
endoplasmic reticulum and to lipid droplets via its N-ter-
minal amphiphatic a-helix. Overexpression of viperin may
lead to a crystalloid ER and has been demonstrated to
reduce protein secretion from HepG2 cells [44, 45]. The
regulation of viperin expression by RNase MRP/P raises
the question whether some of the symptoms of CHH are
due to altered viperin expression levels. Viperin knockout
mice show an impaired Th2 response and T-cell receptor
mediated activation of NF- jB and AP-1 [46]. In another
mouse study, it was shown that viperin is expressed at
higher levels in Th2 cells compared to Th1 cells [47].
These results suggest that viperin may play an important
role in the immune system. An inflammatory trigger may
enhance the expression of viperin via interferon signaling
and this may be needed for an efficient T-cell response.
Subsequently, cells might have to recover from the protein
secretion inhibitory effects of viperin overexpression, by
reducing the levels of viperin and this can at least in part be
achieved by degradation of its mRNA. At this stage RNase
MRP may become activated or may get access to the
mRNAs, e.g., by a subcellular redistribution, to enhance
the degradation of viperin mRNA. Interestingly, CHH
patients indeed express higher levels of viperin in leuko-
cytes compared to healthy controls [37].
The higher expression levels of viperin in CHH patient
leukocytes might result in higher levels of activated NF-jB
and AP-1 as well. Constitutive NF-jB activation has been
observed in various hematological malignancies and solid
tumors [48]. Although it remains to be demonstrated, it is
tempting to speculate that the possibly elevated levels of
active NF-jB due to higher viperin expression in CHH
patient T-cells are associated with the increased risk to
develop hematological cancers.
In rats, the viperin homolog BEST5 is expressed in
bone-forming osteoblast cells during their differentiation
[49]. This suggests that viperin plays a role in the prolif-
eration or differentiation of osteoblasts. No viperin
induction was seen in rat chondrocytes. Chondrocytes are
cells that differentiate into mineralized hypertrophic
chondrocytes before undergoing apoptosis. Osteoblasts and
osteoclasts then remodulate the remaining mineralized
matrix leading to bone deposition. Since RNase MRP is
strongly upregulated in mouse hypertrophic chondrocytes,
and because of the short-limbed dwarfism phenotype of
CHH, it is expected to exert an important function in these
cells [37]. In spite of these observations, more research is
required to investigate whether the deregulation of viperin
expression is involved in the dwarfism phenotype of CHH.
In accordance with the CHH patient microarrays data
mentioned above, the dataset of our microarray analyses
did not show upregulation of human B-type cyclins after
RNase MRP depletion. In addition, we have examined
several CHH patient-derived fibroblasts and fibroblasts
from their relatives, and did not find altered cyclin-B1 or
cyclin-B2 expression levels (unpublished data). Thiel and
coworkers have transfected healthy human fibroblasts with
constructs encoding different RNase MRP RNA mutants
and analyzed the cyclin-B2 mRNA levels by quantita-
tive RT-PCR. Their results showed that transient
expression of the 70A [ G mutant of RNase MRP RNA
significantly increased the expression of the cyclin-B2
mRNA. Interestingly, for most other mutations tested,
they observed a decrease in cyclin-B2 mRNA levels [25].
Taken together, these data do not support a role for RNase
MRP in the regulation of B-type cyclin expression in
human cells.
We conclude that the present study for the first time pro-
vides direct evidence for the cleavage of a mRNA by a human
small nucleolar ribonucleoprotein complex. Cleavage of the
viperin mRNA by RNase MRP/P regulates the expression of
viperin post-transcriptionally and the altered expression levels
of viperin upon a reduction of RNase MRP activity may be
directly involved in the pathogenesis of CHH.
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